You are here
EPIVAX, INC.
UEI: NLAVQM513F18
# of Employees: 28
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: Yes
Award Charts
Award Listing
-
Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities
Amount: $299,917.00ABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and ...
SBIRPhase I2023Department of Health and Human Services National Institutes of Health -
GAA-ITEM: Personalizing the Prediction of Anti-therapeutic Antibody Response in Pompe Disease Patients
Amount: $324,980.00Abstract SignificanceInfantile Pompe DiseaseIPDis an autosomal recessive glycogen storage disorder caused by a deficiency of acid alpha glucosidaseGAAleading to accumulation of glycogen in lysosomespr ...
SBIRPhase I2018Department of Health and Human Services National Institutes of Health -
Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease
Amount: $316,862.00ABSTRACT SignificanceGravesdiseaseGDone of the most prevalent autoimmune diseasesis caused by stimulating autoantibodiesTSAbto the Thyroid Stimulating Hormone ReceptorTSHRresulting in hyperthyroidismC ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Development of a Non adjuvanted VLP Vaccine against Stealth H N Influenza
Amount: $590,546.00DESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of
Amount: $1,474,236.00DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by ...
SBIRPhase II2012Department of Health and Human Services National Institutes of Health -
Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease
Amount: $600,000.00DESCRIPTION (provided by applicant): Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease Pompe disease is a lysosomal storage disorder caused by defects in the enzyme acid alpha-glucosi ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A
Amount: $757,712.00DESCRIPTION (provided by applicant): The goal of this new SBIR program is to produce a combined clotting Factor VIII replacement and immunomodulatory therapy that will provide FVIII-specific tolerance ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
T1D Tolerance Induction with Natural Treg Epitopes
Amount: $599,999.00DESCRIPTION (provided by applicant): Type 1 (juvenile) diabetes is an organ-specific autoimmune disease resulting from destruction of insulinproducing pancreatic beta-cells. In non-diabetics, islet ce ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
Optimization of a Multivalent Tuberculosis Vaccine
Amount: $299,908.00DESCRIPTION (provided by applicant): This new Phase I SBIR proposal addresses the continuing worldwide need for a tuberculosis (TB) vaccine. We detail a novel multivalent strategy that aims to elicit ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health -
Epitope-driven deimmunization of Factor VIII
Amount: $263,867.00DESCRIPTION (provided by applicant): Hemophilia A patients are prone to develop inhibitory immune responses to the very therapy they require: Factor VIII protein replacement. Up to 30% of all hemophil ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health